Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates.

Petro CD, Weinrick B, Khajoueinejad N, Burn C, Sellers R, Jacobs WR Jr, Herold BC.

JCI Insight. 2016 Aug 4;1(12). pii: e88529.

2.

Liposome-Mediated Herpes Simplex Virus Uptake Is Glycoprotein-D Receptor-Independent but Requires Heparan Sulfate.

Burnham LA, Jaishankar D, Thompson JM, Jones KS, Shukla D, Tiwari V.

Front Microbiol. 2016 Jun 22;7:973. doi: 10.3389/fmicb.2016.00973. eCollection 2016.

3.

Approved Antiviral Drugs over the Past 50 Years.

De Clercq E, Li G.

Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi: 10.1128/CMR.00102-15. Review.

PMID:
27281742
4.

Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.

Stanfield B, Kousoulas KG.

Curr Clin Microbiol Rep. 2015 Sep 1;2(3):125-136. Epub 2015 Jul 1.

5.

Autophagy interaction with herpes simplex virus type-1 infection.

O'Connell D, Liang C.

Autophagy. 2016;12(3):451-9. doi: 10.1080/15548627.2016.1139262. Epub 2016 Mar 2.

PMID:
26934628
6.

Deciphering Human Cell-Autonomous Anti-HSV-1 Immunity in the Central Nervous System.

Lafaille FG, Ciancanelli MJ, Studer L, Smith G, Notarangelo L, Casanova JL, Zhang SY.

Front Immunol. 2015 May 8;6:208. doi: 10.3389/fimmu.2015.00208. eCollection 2015. Review.

7.

Inactivation of acyclovir-sensitive and -resistant strains of herpes simplex virus type 1 in vitro by photodynamic antimicrobial chemotherapy.

Latief MA, Chikama T, Ko JA, Kiuchi Y, Sakaguchi T, Obana A.

Mol Vis. 2015 May 2;21:532-7. eCollection 2015.

8.

A Phospho-SIM in the Antiviral Protein PML is Required for Its Recruitment to HSV-1 Genomes.

Smith MC, Box AC, Haug JS, Lane WS, Davido DJ.

Cells. 2014 Dec 10;3(4):1131-58. doi: 10.3390/cells3041131.

9.

Thyroid hormone-dependent epigenetic suppression of herpes simplex virus-1 gene expression and viral replication in differentiated neuroendocrine cells.

Figliozzi RW, Chen F, Balish M, Ajavon A, Hsia SV.

J Neurol Sci. 2014 Nov 15;346(1-2):164-73. doi: 10.1016/j.jns.2014.08.017. Epub 2014 Aug 20.

10.

Self-assembled or mixed peptide amphiphile micelles from Herpes simplex virus glycoproteins as potential immunomodulatory treatment.

Accardo A, Vitiello M, Tesauro D, Galdiero M, Finamore E, Martora F, Mansi R, Ringhieri P, Morelli G.

Int J Nanomedicine. 2014 May 7;9:2137-48. doi: 10.2147/IJN.S57656. eCollection 2014.

11.

Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice.

Matundan H, Mott KR, Ghiasi H.

J Virol. 2014 Jul;88(14):8016-27. doi: 10.1128/JVI.00913-14. Epub 2014 May 7.

12.

Detection and differentiation of herpes simplex viruses by use of the viper platform: advantages, limitations, and concerns.

Lang AL, Roberts C, Mazzulli T, Hatchette TF, LeBlanc JJ.

J Clin Microbiol. 2014 Jun;52(6):2186-8. doi: 10.1128/JCM.03636-13. Epub 2014 Apr 2.

13.

Nelfinavir inhibits maturation and export of herpes simplex virus 1.

Kalu NN, Desai PJ, Shirley CM, Gibson W, Dennis PA, Ambinder RF.

J Virol. 2014 May;88(10):5455-61. doi: 10.1128/JVI.03790-13. Epub 2014 Feb 26.

14.

Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics.

Pediatr Infect Dis J. 2013 Nov;32 Suppl 2:i-KK4. doi: 10.1097/01.inf.0000437856.09540.11. No abstract available.

15.

Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring.

Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, Hamblin MR.

Semin Cutan Med Surg. 2013 Mar;32(1):41-52. Review.

16.

Design, synthesis and antiviral activity studies of schizonepetin derivatives.

Bao B, Meng Z, Li N, Meng Z, Zhang L, Cao Y, Yao W, Shan M, Ding A.

Int J Mol Sci. 2013 Aug 20;14(8):17193-203. doi: 10.3390/ijms140817193.

17.

The role of cytidine deaminases on innate immune responses against human viral infections.

Vieira VC, Soares MA.

Biomed Res Int. 2013;2013:683095. doi: 10.1155/2013/683095. Epub 2013 Jun 25. Review.

18.

Synergistic control of herpes simplex virus pathogenesis by IRF-3, and IRF-7 revealed through non-invasive bioluminescence imaging.

Murphy AA, Rosato PC, Parker ZM, Khalenkov A, Leib DA.

Virology. 2013 Sep;444(1-2):71-9. doi: 10.1016/j.virol.2013.05.034. Epub 2013 Jun 16.

19.

Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.

Schiffer JT, Corey L.

Nat Med. 2013 Mar;19(3):280-90. doi: 10.1038/nm.3103.

20.

Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.

Bernstein DI, Bellamy AR, Hook EW 3rd, Levin MJ, Wald A, Ewell MG, Wolff PA, Deal CD, Heineman TC, Dubin G, Belshe RB.

Clin Infect Dis. 2013 Feb;56(3):344-51. doi: 10.1093/cid/cis891. Epub 2012 Oct 19.

Items per page

Supplemental Content

Write to the Help Desk